Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
- November 17, 2023
The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a collaborative Phase 0/2 trial of niraparib, supported by GSK, in patients with newly diagnosed glioblastoma with unmethylated MGMT.
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
- November 6, 2023
The Ivy Brain Tumor Center announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
- October 18, 2023
The Ivy Brain Tumor Center announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.
- July 18, 2023
In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI. This innovative approach can deliver highly-concentrated doses of experimental drugs directly to the tumor, potentially bypassing the blood-brain barrier and minimizing systemic side effects.
- June 2, 2023
The Ivy Center proudly announces our participation in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for two Phase 0 clinical trials of infigratinib and niraparib in recurrent high-grade glioma and newly-diagnosed glioblastoma.
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical Officer
- May 23, 2023
The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Division Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute.
- May 1, 2023
The Ivy Brain Tumor Center is leading the way in brain cancer research and treatment. May is Brain Tumor Awareness Month and the Ivy Center has partnered with several major organizations across the state to bring much-needed attention to and support for Brain Tumor Awareness Month.
- November 10, 2022
Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Center, is the recipient of the American Brain Tumor Association’s Discovery Grant, a one-year, $50,000 award, supporting faculty and scientists who propose high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumor care.
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
- September 10, 2022
Presented today at the ESMO Congress, Dr. Nader Sanai announced initial results in our Phase 0 clinical trial evaluating pamiparib in patients with #glioblastoma (NCT04614909). The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients.
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
- September 7, 2022
The Ivy Brain Tumor Center announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment.